1. Modulation of gastrointestinal motility beyond metoclopramide and domperidone
- Author
-
Ahmed Madisch, Karen Nieber, Karin Kraft, B. Vinson, med. Martin Storr, Olaf Kelber, and Heba Abdel-Aziz
- Subjects
Functional dyspepsia ,Evidence-based medicine ,medicine.medical_specialty ,Metoclopramide ,Gastrointestinal Diseases ,Evidenzbasierte Medizin ,Pharmacology toxicology ,Reizdarmsyndrom ,Prokinetic drugs ,Gastroenterology ,Irritable Bowel Syndrome ,Funktionelle Dyspepsie ,Prokinetika ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Irritable bowel syndrome ,Randomized Controlled Trials as Topic ,Plant Extracts ,business.industry ,Main Topic ,General Medicine ,medicine.disease ,Domperidone ,Clinical trial ,Clinical Practice ,Safety profile ,Phytopharmakon ,Cisapride ,030220 oncology & carcinogenesis ,Herbal medicinal product ,030211 gastroenterology & hepatology ,Gastrointestinal Motility ,business ,Phytotherapy ,medicine.drug - Abstract
Summary The prokinetic cisapride, an important therapeutic option in functional gastrointestinal (GI) disorders, was withdrawn from the market 15 years ago due to rare severe side effects. Likewise in 2014, the use of metoclopramide (MCP) and domperidone in functional GI disorders (FGID) was restricted, consequently leaving a therapeutic gap in clinical practice. A systematic review revealed that the herbal medicinal product (HMP) STW 5 presents a therapeutic option equivalent to MCP and cisapride. STW 5 is the only HMP for which efficacy has been shown in randomized controlled clinical trials (RCTs) in functional dyspepsia and irritable bowel syndrome, based on its multitarget effect on numerous etiological factors. Due to an outstanding favorable safety profile, STW 5 allows an effective and safe use in FGID without a limitation of the duration of the treatment.
- Published
- 2017
- Full Text
- View/download PDF